Loading
Saros Therapeutics
Saros Therapeutics is an Illinois company developing nanoparticles that carry immune-activating drugs to immune cells, to help the immune system attack tumours that checkpoint inhibitors do not reach.
Also called: Saros Therapeutics Inc
Overview
Saros Therapeutics describes a proprietary nanoparticle platform that targets innate immune cells for cancer and autoimmune disease, and is based at the Helix 51 incubator at Rosalind Franklin University of Medicine and Science in North Chicago (NIH RePORTER lists Chicago). In fiscal year 2026 NCI awarded it USD 1,164,203 under SBIR grant 1R44CA306545-01A1; the abstract describes nanoparticles that combine manganese with a STING agonist to strengthen STING activation, extend the agonist's half-life and target dendritic cells and macrophages, for intravenous use alongside checkpoint inhibitors in tumours that exclude T cells.
Headquarters
North Chicago, IL, US
Funding
All startupsStartup
Investors not recorded; see the round sources.
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Grant · NCI SBIR Phase II (R44) award 1R44CA306545-01A1: Demonstrating safety and combination therapy potential of a novel nanoparticle delivery system | 2026 | $1M | reporter.nih.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Stage
Startup
Website
Notes
- The website names no cancer type, programme or founding year; the STING and manganese detail is from the award abstract. Read on sarostx.com and NIH RePORTER on 4 November 2026.
Connected
3Similar pages
- IdeaInhaled immune therapy to make the lung hostile to arriving tumour cells
Shares STING & innate immune agonists, Cytokines & engineered cytokines.
- TechnologyEngineered bacteria as living cancer drugs
Shares STING & innate immune agonists, Cytokines & engineered cytokines.
- IdeaEngineered bacteria that live in tumours and manufacture drugs there
Shares STING & innate immune agonists, Cytokines & engineered cytokines.
- TechnologyIn situ vaccination
Shares STING & innate immune agonists, Cytokines & engineered cytokines.
- RoadmapImmunotherapy roadmap: Coley's toxins → checkpoint inhibitors → engineered immunity
Shares STING & innate immune agonists, Cytokines & engineered cytokines.
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
nih.gov · 1
sarostx.com · 1
A source that has moved or gone is reported by the weekly link check. /audit/